ArticleEnzyme and microbial technology2015
Kinetic characterization of a novel endo-β-N-acetylglucosaminidase on concentrated bovine colostrum whey to release bioactive glycans.
Article in Enzyme and microbial technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Substrate Versatility of a Recombinant Bifidobacterial Endoglycosidase:International journal of molecular sciences · 2026Article
- Exploring the Activity of a NovelInternational journal of molecular sciences · 2025Article
- Identification and comparison ofFood chemistry: X · 2025Article
- Human Milk Oligosaccharides: Decoding Their Structural Variability, Health Benefits, and the Evolution of Infant Nutrition.Nutrients · 2024Review
- Role of milk glycome in prevention, treatment, and recovery of COVID-19.Frontiers in nutrition · 2022Review
- Immobilization of a Bifidobacterial Endo-Frontiers in bioengineering and biotechnology · 2022Article
- Potential applications of recombinant bifidobacterial proteins in the food industry, biomedicine, process innovation and glycobiology.Food science and biotechnology · 2021Review
- Potential Applications of Endo-β-Frontiers in nutrition · 2021Review
- In Depth Analysis of the Contribution of Specific Glycoproteins to the Overall Bovine Whey N-Linked Glycoprofile.Journal of agricultural and food chemistry · 2020Article
- Structural insights of two novel N-acetyl-glucosaminidase enzymes through in silico methods.Turkish journal of chemistry · 2020Article
- Immobilization of an Endo-β-Catalysts (Basel, Switzerland) · 2018Article
- Utilization of Host-Derived Glycans by IntestinalFrontiers in microbiology · 2018Review
- Bifidobacteria and the infant gut: an example of co-evolution and natural selection.Cellular and molecular life sciences : CMLS · 2018Review
- Characterization of recombinant human lactoferrin N-glycans expressed in the milk of transgenic cows.PloS one · 2017Article
- Recent advances in immobilization strategies for glycosidases.Biotechnology progress · 2017Review
- Oligosaccharides Released from Milk Glycoproteins Are Selective Growth Substrates for Infant-Associated Bifidobacteria.Applied and environmental microbiology · 2016Article
- Characterizing the release of bioactive N-glycans from dairy products by a novel endo-β-N-acetylglucosaminidase.Biotechnology progressArticle
- A novel endo-β-N-acetylglucosaminidase releases specific N-glycans depending on different reaction conditions.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
EndoBI-1 is a recently isolated endo-β-N-acetylglucosaminidase, which cleaves the N-N'-diacetyl chitobiose moiety found in the N-glycan core of high mannose, hybrid and complex N-glycans. These N-glycans have selective prebiotic activity for a key infant gut microbe, Bifidobacterium longum subsp. infantis. The broad specificity of EndoBI-1 suggests the enzyme may be useful for many applications, particularly for deglycosylating milk glycoproteins in dairy processing. To facilitate its commercial use, we determined kinetic parameters for EndoBI-1 on the model substrates ribonuclease B and bovine lactoferrin, as well as on concentrated bovine colostrum whey. Km values ranging from 0.25 to 0.49, 0.43 to 1.00 and 0.90 to 3.18 mg/mL and Vmax values ranging from 3.5×10(-3) to 5.09×10(-3), 4.5×10(-3) to 7.75×10(-3) and 1.9×10(-2)to 5.2×10(-2) mg/mL×min were determined for ribonuclease B, lactoferrin and whey, respectively. In general, EndoBI-1 showed the highest apparent affinity for ribonuclease B, while the maximum reaction rate was the highest for concentrated whey. EndoBI-1-released N-glycans were quantified by a phenol-sulphuric total carbohydrate assay and the resultant N-glycan structures monitored by nano-LC-Chip-Q-TOF MS. The kinetic parameters and structural characterization of glycans released suggest EndoBI-1 can facilitate large-scale release of complex, bioactive glycans from a variety of glycoprotein substrates. Moreover, these results suggest that whey, often considered as a waste product, can be used effectively as a source of prebiotic N-glycans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.